#Japan #medical supplies #Nagasaki #Alfresa Group #Technosuzuta

Alfresa Group Expands Its Horizons with the Acquisition of Technosuzuta

In a significant strategic move aimed at bolstering its supply chain capabilities, Alfresa Group has entered into an agreement to acquire Technosuzuta, a specialized medical wholesaler headquartered in Nagasaki. The acquisition involves purchasing 100% of Technosuzuta’s shares from Onsendou, marking a pivotal step in enhancing Alfresa’s operations in the Kyushu region.

Background and Objectives

The decision is a part of Alfresa Group's broader growth strategy known as the “Alfresa Group Mid-Long Term Vision,” which is targeted towards 2032. The group aims to reinforce its Total Supply Chain Services (TSCS) as a central pillar in its strategic framework. In particular, the company's focus is on strengthening existing alliances and self-operated initiatives within the medical and pharmaceutical wholesale business segment. This underscores a commitment to enhance a nationwide network focused on distributing pharmaceutical products and medical supplies, as highlighted in their 25-27 Medium-Term Management Plan.

Earlier this year, on February 28, Alfresa successfully acquired all shares of Miyazaki Onsendou Shouten, another significant player in the medical supply chain, further solidifying their foothold in the region. Technosuzuta has a longstanding history of over 70 years in the wholesale distribution of diagnostic products, contributing greatly to various sectors such as healthcare, research, and welfare in the Nagasaki prefecture. Their expertise and existing infrastructure provide a perfect fit to enhance Alfresa’s medical supply network.

The acquisition of Technosuzuta not only aims to expand its wholesale business in medical, research, and welfare fields but also seeks to significantly strengthen its distribution network in the Kyushu area, ultimately enhancing contributions to local healthcare services.

Technosuzuta's solid reputation in providing stable supply chains for hospitals, clinics, universities, and care facilities will likely aid Alfresa in achieving their targeted growth objectives through improved efficiency and service delivery.

Details of the Acquisition

• - Acquisition Target: Technosuzuta, a subsidiary primarily focused on clinical and research diagnostic products and medical equipment.
• - Acquisition Date: The stock transfer agreement was signed on February 27, 2026, and the acquisition is expected to be completed by March 31, 2026.
• - Future Projections: While the immediate financial impact of this acquisition on Alfresa's fiscal results for 2026 is expected to be minimal, the long-term advantages are anticipated to significantly enhance the group's corporate value.

The company's strategic direction aims not only at expansion but also at a commitment to improving local healthcare networks through enhanced distribution capabilities and a robust supplier network. Alfresa Group plans to keep stakeholders updated on any significant developments related to this acquisition, ensuring transparency throughout the process.

As Alfresa continues to navigate the complexities of the healthcare supply chain landscape, this acquisition stands as a testament to its forward-thinking approach, and is part of a broader vision to remain at the forefront of the industry by continuously evolving its business strategies to meet future demands.

In conclusion, the acquisition of Technosuzuta marks an important chapter in Alfresa Group's efforts to enhance healthcare services in Japan, reflecting a dedication to not only business growth but also the welfare of communities by contributing to effective medical supply chains.